Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tonix Pharmaceuticals

20.04
+0.85004.43%
Volume:607.56K
Turnover:12.12M
Market Cap:149.77M
PE:-0.11
High:21.10
Open:19.35
Low:18.78
Close:19.19
Loading ...

Tonix Pharmaceuticals Holding Corp reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
Yesterday

Tonix Pharmaceuticals Q1 EPS $(2.84) Beats $(3.37) Estimate, Sales $2.43M Miss $2.55M Estimate

Benzinga
·
Yesterday

Tonix Pharmaceuticals: Current Cash Sufficient to Fund Operations Into Q2 of 2026

THOMSON REUTERS
·
Yesterday

Tonix Pharmaceuticals Held Annual Shareholders Meeting

Reuters
·
09 May

Tonix Pharmaceuticals Unveils Presentation on Advancements in Therapeutics for Pain and Neurologic Conditions

Reuters
·
01 May

BRIEF-Tonix Pharmaceuticals Holding Corp - Discontinued Enrollment And Terminated Phase 2 Catalyst Study - SEC Filing

Reuters
·
26 Apr

BRIEF-Tonix Pharmaceuticals Presented Data On Potential Mpox Vaccine TNX-801 At World Vaccine Congress Washington 2025

Reuters
·
24 Apr

BRIEF-Tonix Pharmaceuticals Announces Oral Presentation And Panel Participation At The World Vaccine Congress Washington 2025

Reuters
·
16 Apr

Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025

THOMSON REUTERS
·
16 Apr

BRIEF-Tonix Pharmaceuticals And Makana Therapeutics Announce Collaboration Combining Tonix’S Anti-Cd40l Monoclonal Antibody (Tnx-1500) With Makana’S Genetically Engineered Organs In Preclinical And Clinical Xenotransplantation Studies

Reuters
·
09 Apr

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-Cd40l Monoclonal Antibody (Tnx-1500) With Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

THOMSON REUTERS
·
09 Apr

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

GlobeNewswire
·
09 Apr

Tonix Pharmaceuticals presents data, analyses of TNX-102 SL effects

TIPRANKS
·
07 Apr

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

GlobeNewswire
·
07 Apr

Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year

ACCESS Newswire
·
31 Mar

New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc.

ACCESS Newswire
·
29 Mar